About the Program
In 2012, Bayer launched the Global Ophthalmology Awards Program (GOAP) with the aim of advancing the scientific understanding and clinical management of retinal ophthalmic disorders. Through grants supporting research and training in ophthalmology, the program seeks to provide opportunities for treatment improvement and to encourage ophthalmologists to further develop their skills in the management of retinal disorders.
Who Are We?
The Bayer Group is a global enterprise with core competencies in the fields of healthcare, nutrition and high-tech materials. Bayer, a subgroup of Bayer AG, with annual sales of EUR 46.8 billion (2016), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer's aim is to discover and manufacture products that will improve human and animal health worldwide. Bayer has a global workforce of 115,200 employees (Dec 31, 2016) and is represented in more than 100 countries. Find more information at www.pharma.bayer.com.
Bayer envisions the GOAP as a step toward making the dream of ophthalmology cures and improved treatments a reality.
The GOAP demonstrates our commitment to the global ophthalmic disorders community and to advancing state-of-the-art ophthalmic care.